Skip to content

Atosiban (6.75 mg) injection to delay preterm birth

An Open-Label, placebo controlled Study to Evaluate the Efficacy and Safety of Atosiban 6.75 mg/0.9ml in Preterm Labor

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/11/010518
Enrollment
75
Registered
2017-11-15
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O60- Preterm labor Health Condition 2: O60- Preterm labor

Interventions

Intervention1: Atosiban: 6.75mg atosiban intravenous bolus injection once given over 1 minute Control Intervention1: Placebo: 0.9 ml intravenous bolus injection once given over 1 minute

Sponsors

Zuventus Healthcare Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women =18 years of age Gestational age from 24 until 33 completed weeks which has been documented by a definite LMP or sonography in the first trimester Women with preterm labor. The diagnosis of preterm labor requires the presence of uterine contractions with or without cervical changes

Exclusion criteria

Exclusion criteria: Women with any of the following: Chorioamnionitis Preterm rupture of membranes Vaginal bleeding Eclampsia and severe pre-eclampsia requiring delivery Intrauterine growth restriction Intrauterine fetal death Congenital or acquired uterine malformation Severe placental insufficiency Placenta previa and abruptio placentae Fetal distress Women who are otherwise judged inappropriate for inclusion in the study by the investigator.

Design outcomes

Primary

MeasureTime frame
Evaluation of time gained in utero after initiation of treatment for 48 hrsTimepoint: Till delivery

Secondary

MeasureTime frame
Evaluation of safety and tolerabilityTimepoint: till delivery

Countries

India

Contacts

Public ContactDr Bhupesh Dewan

Zuventus Healthcare Ltd

Bhupesh.Dewan@zuventus.com28472823

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026